Affordable Access

deepdyve-link
Publisher Website

Wedelolactone induces growth of breast cancer cells by stimulation of estrogen receptor signalling.

Authors
  • Nehybova, Tereza
  • Smarda, Jan
  • Daniel, Lukas
  • Brezovsky, Jan
  • Benes, Petr
Type
Published Article
Journal
The Journal of Steroid Biochemistry and Molecular Biology
Publisher
Elsevier
Publication Date
Aug 01, 2015
Volume
152
Pages
76–83
Identifiers
DOI: 10.1016/j.jsbmb.2015.04.019
PMID: 25934092
Source
Medline
Keywords
License
Unknown

Abstract

Wedelolactone, a plant coumestan, was shown to act as anti-cancer agent for breast and prostate carcinomas in vitro and in vivo targeting multiple cellular proteins including androgen receptors, 5-lipoxygenase and topoisomerase IIα. It is cytotoxic to breast, prostate, pituitary and myeloma cancer cell lines in vitro at μM concentrations. In this study, however, a novel biological activity of nM dose of wedelolactone was demonstrated. Wedelolactone acts as agonist of estrogen receptors (ER) α and β as demonstrated by transactivation of estrogen response element (ERE) in cells transiently expressing either ERα or ERβ and by molecular docking of this coumestan into ligand binding pocket of both ERα and ERβ. In breast cancer cells, wedelolactone stimulates growth of estrogen receptor-positive cells, expression of estrogen-responsive genes and activates rapid non-genomic estrogen signalling. All these effects can be inhibited by pretreatment with pure ER antagonist ICI 182,780 and they are not observed in ER-negative breast cancer cells. We conclude that wedelolactone acts as phytoestrogen in breast cancer cells by stimulating ER genomic and non-genomic signalling pathways.

Report this publication

Statistics

Seen <100 times